Literature DB >> 27456985

A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children.

Alana T Brennan1, Rachael Bonawitz, Christopher J Gill, Donald M Thea, Mary Kleinman, Johanna Useem, Lindsey Garrison, Rachel Ceccarelli, Chinenye Udokwu, Lawrence Long, Matthew P Fox.   

Abstract

OBJECTIVE: Conduct a meta-analysis examining differential all-cause mortality rates between HIV-exposed uninfected (HEU) infants and children as compared with their HIV-unexposed uninfected (HUU) counterparts.
DESIGN: Meta-analysis summarizing the difference in mortality between HEU and HUU infants and children. Reviewed studies comparing children in the two groups for all-cause mortality, in any setting, from 1994 to 2016 from six databases.
METHODS: Meta-analyses were done estimating overall mortality comparing the two groups, stratified by duration of follow-up time from birth (0-12, 12-24 and >24 months) and by year enrollment ended in each study: less than 2002 compared with at least 2002, when single-dose nevirapine for prevention of mother-to-child transmission (PMTCT) commenced in low-income and middle-income countries.
RESULTS: Included 22 studies, for a total of 29 212 study participants [n = 8840 (30.3%) HEU; n = 20 372 (37.7%) HUU]. Random effects models showed HEU had a more than 70% increased risk of mortality vs. HUU. Stratifying by age showed that HEU vs. HUU had a significant 60-70% increased risk of death at every age strata. There was a significant 70% increase in the risk of mortality between groups before the implementation of PMTCT, which remained after 2002 [risk ratio: 1.46; 95% confidence interval (CI): 1.14-1.87], when the availability of PMTCT services was widespread, suggesting that prenatal antiretroviral therapy, and healthier mothers, does not fully eliminate this increased risk in mortality.
CONCLUSION: We show a consistent increase risk of mortality for HEU vs. HUU infants and children. Longitudinal research is needed to elucidate underlying mechanisms, such as maternal and infant health status and breast feeding practices, which may help explain these differences in mortality.

Entities:  

Mesh:

Year:  2016        PMID: 27456985     DOI: 10.1097/QAD.0000000000001211

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  57 in total

1.  Considerations in evaluating infectious morbidity and mortality in HIV-exposed uninfected infants.

Authors:  Amy L Slogrove; Kathleen M Powis; Julie A Bettinger; Mark F Cotton
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

2.  Human Immunodeficiency Virus-exposed Uninfected Infants: Surviving and Thriving or Overlooked by Success?

Authors:  Amy L Slogrove; Kathleen M Powis; Mark F Cotton
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

Review 3.  Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.

Authors:  Amy L Slogrove; Polly Clayden; Elaine J Abrams
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

4.  Co-trimoxazole Prophylaxis, Asymptomatic Malaria Parasitemia, and Infectious Morbidity in Human Immunodeficiency Virus-Exposed, Uninfected Infants in Malawi: The BAN Study.

Authors:  Nicole L Davis; Jeffrey Wiener; Jonathan J Juliano; Linda Adair; Charles S Chasela; Dumbani Kayira; Michael G Hudgens; Charles van der Horst; Denise J Jamieson; Athena P Kourtis
Journal:  Clin Infect Dis       Date:  2017-08-15       Impact factor: 9.079

5.  Protecting the health of our AIDS-free generation: beyond prevention of mother-to-child HIV transmission.

Authors:  Kathleen M Powis; Amy L Slogrove; Lynne Mofenson
Journal:  AIDS       Date:  2017-01-14       Impact factor: 4.177

6.  Widening the Lens to Ensure Children Who Are Human Immunodeficiency Virus (HIV) Exposed Are Alive, HIV Free, and Thriving.

Authors:  Amy L Slogrove; Kathleen M Powis
Journal:  Clin Infect Dis       Date:  2021-02-16       Impact factor: 9.079

7.  Cotrimoxazole Prophylaxis Selects for Antimicrobial Resistance in Human Immunodeficiency Virus-Exposed, Uninfected Infants.

Authors:  Claire D Bourke; Ceri Evans
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

Review 8.  Contemporary Issues in Pregnancy (and Offspring) in the Current HIV Era.

Authors:  Allison Ross Eckard; Stephanie E Kirk; Nancy L Hagood
Journal:  Curr HIV/AIDS Rep       Date:  2019-12       Impact factor: 5.071

9.  Determinants of growth in HIV-exposed and HIV-uninfected infants in the Kabeho Study.

Authors:  Charlotte E Lane; Emily A Bobrow; Diuedonne Ndatimana; Gilles F Ndayisaba; Linda S Adair
Journal:  Matern Child Nutr       Date:  2019-01-29       Impact factor: 3.092

10.  HIV-exposed-uninfected infants have increased inflammation and monocyte activation.

Authors:  Sahera Dirajlal-Fargo; Marisa M Mussi-Pinhata; Adriana Weinberg; Qilu Yu; Rachel Cohen; D Robert Harris; Emily Bowman; Janelle Gabriel; Manjusha Kulkarni; Nicholas Funderburg; Nahida Chakhtoura; Grace A McComsey
Journal:  AIDS       Date:  2019-04-01       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.